| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1007836256 |
| P356 | DOI | 10.2165/00003495-199958030-00003 |
| P698 | PubMed publication ID | 10493270 |
| P50 | author | Vassilios Fanos | Q37835030 |
| P2093 | author name string | A Dall'Agnola | |
| P2860 | cites work | Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981 | Q24671879 |
| Chloramphenicol toxicity in neonates: its incidence and prevention | Q24675357 | ||
| Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy | Q28300540 | ||
| Methicillin-associated nephropathy or cystitis | Q28331527 | ||
| Nephrotoxicity of vancomycin, alone and with an aminoglycoside | Q28335291 | ||
| Treatment of meningitis and septicemia in infancy with a sulphamethoxazole/trimethorpim combination | Q28336535 | ||
| Cardiac arrest associated with vancomycin in a neonate | Q28367799 | ||
| Mechanisms of cephalosporin nephrotoxicity: a comparison of cephaloridine and cephaloglycin | Q29041179 | ||
| Imipenem/Cilastatin | Q29400850 | ||
| Antimicrobial therapy for pediatric patients | Q33429288 | ||
| Pneumonia in neonates: can it be managed in the community? | Q33623341 | ||
| Cefaclor into the millennium | Q33704403 | ||
| Pharmacokinetics of nafcillin in infants with low birth weights | Q33727495 | ||
| Single-dose pharmacokinetics of aztreonam in pediatric patients | Q33737281 | ||
| Ticarcillin-clavulanic acid pharmacokinetics in preterm neonates with presumed sepsis | Q33758314 | ||
| Cefuroxime in the treatment of neonates | Q33825285 | ||
| Antibiotic prophylaxis in children with relapsing urinary tract infections: review | Q33902960 | ||
| Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. | Q34193382 | ||
| Prospective, randomized, controlled evaluation of a gentamicin loading dose in neonates | Q72233577 | ||
| Renal function in premature infants during aminoglycoside therapy | Q72343532 | ||
| [The course of congenital toxoplasmosis. Critical study of 12 treated cases] | Q72389079 | ||
| [Continuous infusion of vancomycin during the neonatal period] | Q72416062 | ||
| Effects of cefotaxime on the proximal tubules of the human kidney | Q72431937 | ||
| Erythromycin lactobionate toxicity in preterm neonates | Q72438642 | ||
| Ceftriaxone versus ampicillin and chloramphenicol for treatment of bacterial meningitis in children | Q72553702 | ||
| Development of glomerular filtration rate and excretion of beta 2-microglobulin in neonates during gentamicin treatment | Q72694223 | ||
| Pharmacokinetic studies of mezlocillin in newborn infants | Q72754290 | ||
| Transplacental effects of gentamicin on endocytosis in rat renal proximal tubule cells | Q72771773 | ||
| Adverse Reactions to Vancomycin Used as Prophylaxis for CSF Shunt Procedures | Q72804128 | ||
| Antistaphylococcal Activity of Rifampin with Other Antibiotics | Q72909243 | ||
| Gentamicin pharmacokinetics in neonates with patent ductus arteriosus | Q73075628 | ||
| [Aminoglycosides, risk factors and neonatal kidney] | Q73118305 | ||
| Effect of time and temperature on inactivation of aminoglycosides by ampicillin at neonatal dosages | Q73152759 | ||
| Tobramycin and gentamicin are equally safe for neonates: results of a double-blind randomized trial with quantitative assessment of renal function | Q73421962 | ||
| Toxic nephropathies | Q73468864 | ||
| Therapeutic drug monitoring of gentamicin: a 6-year follow-up audit | Q73686157 | ||
| [Infections of the urinary tract in the newborn and infants] | Q74285001 | ||
| [Glycopeptides and the newborn infant's kidney] | Q74331379 | ||
| STUDIES OF PREMATURES GIVEN ERYTHROMYCIN ESTOLATE | Q76538125 | ||
| Renal tolerability of teicoplanin in a case of neonatal overdose | Q77580053 | ||
| Control of an outbreak of a highly beta-lactam-resistant Enterobacter cloacae strain in a neonatal special care unit | Q77591319 | ||
| Unlicensed and off label drug use for paediatric patients. Optimal dosing schedules with gentamicin are needed for premature neonates | Q95807394 | ||
| Serum vancomycin concentrations: reappraisal of their clinical value | Q34330702 | ||
| Pharmacokinetics and antibacterial activity of daily gentamicin | Q35066606 | ||
| Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children | Q35117064 | ||
| Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant | Q35248648 | ||
| Treatment options for the pharmacological therapy of neonatal meningitis | Q35329151 | ||
| Diagnosis and management of meningitis | Q35536782 | ||
| Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, and cefotaxime-desacetylcefotaxime in the presence of human serum | Q35540563 | ||
| In vitro displacement of bilirubin by antibiotics and 2-hydroxybenzoylglycine in newborns | Q35564504 | ||
| Antibiotic use in the neonatal unit | Q35603575 | ||
| Third-generation cephalosporins: a review | Q35609902 | ||
| Infantile meningitis in England and Wales: a two year study | Q35626438 | ||
| Pharmacokinetics of carbenicillin in neonates of normal and low birth weight | Q35643461 | ||
| Piperacillin pharmacokinetics in pediatric patients | Q35716595 | ||
| Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis | Q35718258 | ||
| Pharmacokinetic properties of mezlocillin in newborn infants | Q35759629 | ||
| Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs | Q35763012 | ||
| Endotoxemia, renal hypoperfusion, and fever: interactive risk factors for aminoglycoside and sepsis-associated acute renal failure | Q35804349 | ||
| Light- and electron-microscopic analysis of the kidney in newborn rats exposed to gentamicin in utero. | Q35818318 | ||
| Vancomycin and teicoplanin: something old, something new. | Q35863131 | ||
| Safety profile and efficacy of cefotaxime for the treatment of hospitalized children | Q36043831 | ||
| Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982. | Q36493837 | ||
| Emergence of teicoplanin-resistant coagulase-negative staphylococci | Q36535437 | ||
| The use of aztreonam in pediatric patients: a review | Q37331140 | ||
| Coagulase-negative staphylococcal infections in neonates | Q37661560 | ||
| Drug-induced nephrotoxicity. Aetiology, clinical features and management | Q37740051 | ||
| Delayed cerebrospinal fluid sterilization, in vitro bactericidal activities, and side effects of selected beta-lactams. | Q37797081 | ||
| Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential | Q37860938 | ||
| Treatment of chlamydial conjunctivitis in newborns and adults with erythromycin and roxithromycin | Q37894615 | ||
| Erythromycin: a microbial and clinical perspective after 30 years of clinical use (2). | Q37904546 | ||
| The use of antibiotics in neonates weighing less than 1200 grams. | Q37907469 | ||
| Pharmacokinetics of erythromycin ethylsuccinate and estolate in infants under 4 months of age. | Q37909232 | ||
| Serious pediatric infections | Q37915934 | ||
| Safety of parenteral third-generation cephalosporins | Q37915964 | ||
| Clinical pharmacokinetics of antibacterial drugs in neonates | Q37956835 | ||
| Metabolism and effects of epidermal growth factor and related growth factors in mammals | Q37977466 | ||
| Vancomycin pharmacokinetics and dosing in premature neonates | Q71544248 | ||
| Teicoplanin pharmacology in prophylaxis for coagulase-negative staphylococcal sepsis of very low birthweight infants | Q71580350 | ||
| Comparative bioavailability and pharmacokinetics of chloramphenicol after intravenous chloramphenicol succinate in premature infants and older patients | Q71705160 | ||
| Sepsis with coagulase-negative staphylococci in critically ill newborns | Q71722293 | ||
| Evaluation of antibiotic-induced nephrotoxicity in preterm neonates by determining urinary alpha 1-microglobulin | Q71737544 | ||
| Neonatal septicemia | Q71748612 | ||
| Application of new sepsis definitions to evaluate outcome of pediatric patients with severe systemic infections | Q71762035 | ||
| Urinary excretion of adenosine deaminase binding protein in neonates treated with tobramycin | Q71784882 | ||
| Serum concentrations of erythromycin after intravenous infusion in preterm neonates treated for Ureaplasma urealyticum infection | Q72072068 | ||
| Once daily aminoglycoside dosing in full term neonates | Q72154250 | ||
| Renal tubular transport and nephrotoxicity of beta lactam antibiotics: structure-activity relationships | Q40585464 | ||
| Synergistic Effects of Ampicillin-Aminoglycoside Combinations on Group B Streptococci | Q40620226 | ||
| Vancomycin toxicity. What is the evidence for dose dependency? | Q40627165 | ||
| Principles of drug administration in renal insufficiency | Q40659419 | ||
| Uncommon pathogens in newborn infants. | Q40663042 | ||
| Pharmacokinetics of anti-infective agents in paediatric patients | Q40686147 | ||
| Adverse drug reactions in neonates | Q40743354 | ||
| Infection in the immunocompromised host | Q40818264 | ||
| Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. | Q40827402 | ||
| Moxalactam therapy of Haemophilus influenzae type b meningitis in children | Q40828835 | ||
| Chloramphenicol: properties and clinical use. | Q40843368 | ||
| Comparative toxicities of methicillin and nafcillin | Q40856782 | ||
| Adverse effects of newer cephalosporins. An update | Q40858398 | ||
| Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children | Q40888996 | ||
| Renal and electrolyte complications associated with antibiotic therapy. | Q40937439 | ||
| Amikacin in newborn infants: comparative pharmacology with kanamycin and clinical efficacy in 45 neonates with bacterial diseases | Q40947006 | ||
| The evolution of aminoglycoside therapy: a single daily dose | Q40982783 | ||
| Bayesian forecasting of serum vancomycin concentrations in neonates and infants. | Q40984108 | ||
| Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis | Q40988370 | ||
| Intravenous trimethoprim-sulfamethoxazole in the treatment of serious infections in children | Q41108916 | ||
| Pharmacokinetic determinants of carbapenem therapy in neonates and children | Q41153383 | ||
| Pneumocystis carinii pneumonia in infants after heart transplantation. | Q41173226 | ||
| Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose | Q41174871 | ||
| Meropenem: a new, extremely broad spectrum beta-lactam antibiotic for serious infections in pediatrics | Q41390923 | ||
| Pharmacokinetics of intramuscular carbenicillin in the newborn | Q41449266 | ||
| A review of teicoplanin in the treatment of serious neonatal infections | Q41518598 | ||
| Antibacterial activity of ticarcillin in the presence of clavulanate potassium | Q41523935 | ||
| Nephrotoxicity of beta-lactam antibiotics: mechanisms and strategies for prevention | Q41686944 | ||
| Beta-lactam antibiotics: their role in the management of infections in children | Q41728584 | ||
| Ceftazidime in neonatal infections | Q41768640 | ||
| Neonatal Sepsis in Pakistan: Presentation and Pathogens | Q41837800 | ||
| Constant rate infusion of vancomycin in premature neonates: a new dosage schedule | Q41883396 | ||
| A multicentre open clinical trial of teicoplanin in infections caused by gram-positive bacteria | Q42067909 | ||
| Outbreak of cephalosporin resistant Enterobacter cloacae infection in a neonatal intensive care unit | Q42138748 | ||
| Single or multiple daily doses of aminoglycosides: a meta-analysis | Q42145555 | ||
| Seizure propensity with imipenem | Q42196167 | ||
| Ceftriaxone-associated cholecystitis. | Q42212515 | ||
| A controlled study of the nephrotoxicity of mezlocillin and gentamicin plus ampicillin in the neonate | Q42212798 | ||
| Aminoglycoside-related nephrotoxicity in the premature newborn | Q42247730 | ||
| Clinical nephrotoxicity of tobramycin and gentamicin. A prospective study | Q42273022 | ||
| Fatal hemolysis induced by ceftriaxone in a child with sickle cell anemia | Q42279188 | ||
| Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination | Q42286407 | ||
| Tobramycin population pharmacokinetics in neonates. | Q42666715 | ||
| Single or multiple daily doses of aminoglycosides. More details needed of treatment in neonates and young children | Q42742563 | ||
| Teicoplanin therapy in neonatal and pediatric intensive therapy | Q43445181 | ||
| Once-daily ceftriaxone to complete therapy of uncomplicated group B streptococcal infection in neonates. A preliminary report | Q43453771 | ||
| Nosocomial bacterial infections in very low birth weight infants | Q43477048 | ||
| Current therapy of bacterial sepsis and meningitis in infants and children: a poll of directors of programs in pediatric infectious diseases | Q43532718 | ||
| Ceftazidime in the treatment of neonatal infection | Q43582090 | ||
| Incidence and etiology of neonatal septicaemia and meningitis in western Sweden 1975-1986. | Q43603498 | ||
| Multi-resistant Staphylococcus haemolyticus in a neonatal unit in New Delhi | Q43608703 | ||
| Nosocomial infections among neonates in high-risk nurseries in the United States. National Nosocomial Infections Surveillance System | Q43970844 | ||
| Maturational changes and origin of urinary human epidermal growth factor in the neonatal period | Q43985120 | ||
| Clinical pharmacology of methicillin in neonates | Q44005207 | ||
| Impact of cefaclor on the normal human oropharyngeal and intestinal microflora | Q44028145 | ||
| Comparative toxicities of third-generation cephalosporins | Q44035742 | ||
| Predictability of peak serum gentamicin concentration with dosage based on body surface area | Q44048762 | ||
| Cefotaxime treatment of gram-negative enteric meningitis in infants and children | Q44262891 | ||
| Preliminary experience with ceftazidime monotherapy in perinatal infection | Q44273392 | ||
| Emergence of vancomycin resistance in coagulase-negative staphylococci | Q44441075 | ||
| Ticarcillin plus clavulanic acid (Timentin) compared with standard antibiotic regimes in the treatment of early and late neonatal infections | Q44456022 | ||
| Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 | ||
| Pharmacokinetics of intravenous clindamycin in newborn infants. | Q44530694 | ||
| Evaluation of aztreonam and ampicillin vs. amikacin and ampicillin for treatment of neonatal bacterial infections | Q44542204 | ||
| Early indicators of nephrotoxicity: comparison of two antibiotics | Q44636770 | ||
| Use of teicoplanin in preterm neonates with staphylococcal late-onset neonatal sepsis | Q44665783 | ||
| Consensus report: antimicrobial therapy for bacterial meningitis in infants and children | Q44666575 | ||
| Pharmacokinetic study of sulbactam and ampicillin administered concomitantly by intraarterial or intravenous infusion in the newborn | Q44682882 | ||
| Five years of cefotaxime use in a neonatal intensive care unit. | Q44745422 | ||
| Nosocomial sepsis in the neonatal intensive care unit | Q44807134 | ||
| Selective use of vancomycin to prevent coagulase-negative staphylococcal nosocomial bacteremia in high risk very low birth weight infants | Q44809658 | ||
| Ceftazidime or gentamicin plus benzylpenicillin in neonates less than forty-eight hours old | Q44824529 | ||
| Low-dose vancomycin prophylaxis reduces coagulase-negative staphylococcal bacteraemia in very low birthweight infants | Q44838580 | ||
| Vancomycin-associated shock and rash in newborn infants | Q44901572 | ||
| Should we use vancomycin as prophylaxis to prevent neonatal nosocomial coagulase-negative staphylococcal septicemia? | Q44971349 | ||
| Surveillance of antibiotic therapy in a pediatric intensive care unit | Q44996186 | ||
| Pharmacology of trimethoprim-sulfamethoxazole in newborn infants | Q45048038 | ||
| Clinical pharmacology and efficacy of ticarcillin in infants and children | Q45121028 | ||
| Effect of aztreonam on the fecal aerobic flora in children | Q45267405 | ||
| Red man syndrome: incidence, etiology, and prophylaxis. | Q46032651 | ||
| Furosemide Enhancement of Experimental Gentamicin Nephrotoxicity: Comparison of Functional and Morphological Changes with Activities of Urinary Enzymes | Q46036624 | ||
| Early discontinuation of antibiotic treatment in newborns admitted to rule out sepsis: a decision rule | Q46104026 | ||
| A 4-year study of neonatal meningitis: clinical and microbiological findings | Q46262833 | ||
| Early-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network | Q46360821 | ||
| Clinical pharmacology of ticarcillin in the newborn infant: relation to age, gestational age, and weight | Q47346994 | ||
| Prophylactic low-dose vancomycin treatment in very-low-birth-weight infants | Q47420521 | ||
| Increasing incidence of neonatal septicemia: causative organism and predisposing risk factors | Q47715829 | ||
| A pharmacologic evaluation of penicillin in children with purulent meningitis | Q48271822 | ||
| Epidemiological analysis of strains of methicillin-resistant Staphylococcus aureus (MRSA) infection in the nursery; prognosis of MRSA carrier infants | Q50142438 | ||
| Monitoring serum vancomycin levels: climbing the mountain because it is there? | Q50525348 | ||
| Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides for gram-negative infections. | Q50555981 | ||
| Prospective comparative trial of moxalactam versus amplicillin or chloramphenicol for treatment of haemophilus influenzae type b meningitis in children | Q50588958 | ||
| Growth and development in preterm infants receiving fluoroquinolones. | Q51006897 | ||
| Developmental pharmacokinetics of mezlocillin in newborn infants. | Q52274775 | ||
| Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy. | Q52393812 | ||
| PKRD: a pharmacokinetic program for least-squares and bayesian analysis of repeated-dose pharmacokinetic curves. | Q52420862 | ||
| Comparative Pharmacokinetics of Four New Cephalosporins: Moxalactam, Cefotaxime, Cefoperazone and Ceftazidime in Neonates | Q53680865 | ||
| Pharmacokinetics of amikacin in neonates. | Q53732330 | ||
| Fatal hemolysis caused by ceftriaxone. | Q53804496 | ||
| Urinary phospholipids excretion in neonates treated with amikacin | Q53907771 | ||
| Impact of antimicrobial agents on human intestinal microflora | Q37981695 | ||
| Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children. | Q38635660 | ||
| Ceftazidime and cefotaxime--the clinician's choice | Q38648572 | ||
| Piperacillin in early neonatal infection | Q38947381 | ||
| Once versus thrice daily gentamicin in patients with serious infections | Q39369365 | ||
| Aminoglycoside nephrotoxicity and urinary excretion of N-acetyl-beta-D-glucosaminidase | Q39521130 | ||
| Vancomycin ototoxicity and nephrotoxicity. A review | Q39542494 | ||
| Neonatal sepsis. Progress in diagnosis and management | Q39557987 | ||
| Beta-2-microglobulin, an indicator of renal tubular maturation and dysfunction in the newborn | Q39583727 | ||
| The comparative efficacy and safety of teicoplanin and vancomycin | Q39601973 | ||
| A review of drug prescribing in children with end-stage renal failure | Q39611792 | ||
| Aztreonam: review of the clinical experience and potential uses in pediatrics | Q39645907 | ||
| Aminoglycoside nephrotoxicity | Q39648907 | ||
| Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II). | Q39654030 | ||
| Neonatal bilirubin toxicity. A review of kernicterus and the implications of drug-induced bilirubin displacement | Q39665704 | ||
| Clinical Pharmacokinetics of Rifampicin | Q39720647 | ||
| Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. | Q39727896 | ||
| The cephalosporin antibiotics in pediatric therapy | Q39733804 | ||
| Aminoglycoside toxicity in infants and children | Q39738115 | ||
| Adverse reactions and interactions with newer cephalosporin and cephamycin antibiotics | Q39749497 | ||
| Pharmacokinetic interactions of the macrolide antibiotics | Q39814639 | ||
| Pharmacokinetics of teicoplanin in pediatric patients | Q39818673 | ||
| Chloramphenicol: clinical pharmacology in pediatrics. | Q39826117 | ||
| Pharmacokinetics and plasma bactericidal activity of aztreonam in low-birth-weight infants | Q39827478 | ||
| Modern beta-lactam antibiotics | Q39843101 | ||
| Pharmacokinetics of imipenem-cilastatin in neonates | Q39849539 | ||
| Single-dose pharmacokinetics of imipenem-cilastatin in neonates | Q39849620 | ||
| Antibiotic-induced paralysis | Q39866296 | ||
| Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia | Q39882511 | ||
| Pharmacokinetics and renal tolerance of aztreonam in premature infants | Q40087264 | ||
| The cephalosporin compounds in severe neonatal infection | Q40140366 | ||
| Review of the pharmacokinetics of mezlocillin | Q40158227 | ||
| The Acylampicillins: Mezlocillin, Piperacillin, and Azlocillin | Q40173629 | ||
| Cephalosporin-aminoglycoside synergistic nephrotoxicity: fact or fiction? | Q40313792 | ||
| Carbenicillin and ticarcillin. | Q40326279 | ||
| Pathogenesis of nephrotoxicity of cephalosporins and aminoglycosides: a review of current concepts. | Q40347973 | ||
| Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy | Q40391918 | ||
| Renal tubule cell repair following acute renal injury. | Q40416339 | ||
| Prevention of drug-induced nephrotoxicity in the intensive care unit | Q40529807 | ||
| Antibiotic-resistant gram-negative bacteria in the critical care setting | Q40531630 | ||
| Antibiotic-related nephrotoxicity. | Q40555628 | ||
| Antibiotics at the extremes of age: choices and constraints | Q40584583 | ||
| Acute bacterial meningitis in the newborn. | Q40584642 | ||
| A comparative trial of low dose cefaclor and macrocrystalline nitrofurantoin in the prevention of recurrent urinary tract infection. | Q54013704 | ||
| Ceftazidime in common infections in childhood. Experience in 262 cases | Q54076983 | ||
| Ciprofloxacin in preterm neonates: case report and review of the literature. | Q54117521 | ||
| Staphylococcus epidermidisIsolation and Antibiotic Resistance in a Neonatal Intensive Care Unit | Q54181982 | ||
| Impact of ampicillin and cefuroxime on bacterial colonization and infection in patients on a neonatal intensive care unit. | Q54254565 | ||
| A comparison of ceftazidime and aminoglycoside based regimens as empirical treatment in 1316 cases of suspected sepsis in the newborn. European Society for Paediatric Infectious Diseases--Neonatal Sepsis Study Group. | Q54256397 | ||
| Use of Percutaneous Silastic Central Venous Catheters in Neonates and the Management of Infectious Complications | Q54266537 | ||
| Antibiotic susceptibilities and therapeutic options for Ureaplasma urealyticum infections in neonates. | Q54279028 | ||
| Antibiotic therapy in maternal-fetal infections | Q54287952 | ||
| Vancomycin-induced red man syndrome. | Q54314658 | ||
| Use of third-generation cephalosporins for treatment of neonatal infections. | Q54441537 | ||
| Gentamicin vs cefotaxime for therapy of neonatal sepsis. Relationship to drug resistance. | Q54441972 | ||
| Clinical pharmacology and efficacy of vancomycin in pediatric patients. | Q54560810 | ||
| Chloramphenicol in paediatrics: current prescribing practice and the need to monitor. | Q54609196 | ||
| [Importance of the study of the minimal bactericidal time of serum in the choice of optimal treatment of neonatal septicemias] | Q54765316 | ||
| Clinical efficacy of sulbactam/ampicillin in pediatric infections caused by ampicillin-resistant or penicillin-resistant organisms. | Q54773994 | ||
| Methicillin-induced neutropenia. | Q54792918 | ||
| Trough-only monitoring of serum vancomycin concentrations in neonates | Q57976200 | ||
| Influence of Intrauterine Maturation on the Pharmacokinetics of Amikacin in the Neonatal Period | Q61713352 | ||
| Cefotaxime (HR 756) and nephrotoxicity | Q66702166 | ||
| Complete biliary obstruction due to erythromycin estolate administration in an infant | Q66976141 | ||
| Clinical pharmacology of carbenicillin and gentamicin in the neonate and comparative efficacy with ampicillin and gentamicin | Q67271039 | ||
| A half century of neonatal sepsis at Yale: 1928 to 1978 | Q67273293 | ||
| Netilmicin in moderate to severe infections in newborns and infants: a study of efficacy, tolerance and pharmacokinetics | Q67283108 | ||
| Renal function in respiratory distress syndrome | Q67452775 | ||
| Enzymuria in neonates receiving continuous intravenous infusion of gentamicin | Q67515067 | ||
| Therapy of bacterial sepsis, meningitis and otitis media in infants and children: 1992 poll of directors of programs in pediatric infectious diseases | Q67591036 | ||
| Cerebrospinal fluid levels of benzathine penicillin G in the neonate | Q67716889 | ||
| Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients | Q67779622 | ||
| Ampicillin–Aminoglycoside Combinations as Initial Treatment for Neonatal Septicaemia or Meningitis: A Retrospective Evaluation of 12 Years' Experience | Q67786575 | ||
| Glomerular alterations in rat neonates after transplacental exposure to gentamicin | Q67816582 | ||
| Nosocomial pneumonia: comparative multicentre trial between monotherapy with cefotaxime and treatment with antibiotic combinations | Q67858753 | ||
| Pharmacokinetics and Bioavailability of a New Formulation of Teicoplanin following Intravenous and Intramuscular Administration to Humans | Q67904144 | ||
| Ciprofloxacin in neonates and its possible adverse effect on the teeth | Q67972130 | ||
| Renal injury in sick newborn infants: a prospective evaluation using urinary beta 2-microglobulin concentrations | Q68127461 | ||
| Urinary excretion of N-acetyl-glucosaminidase and beta-2-microglobulin as early markers of gentamicin nephrotoxicity in neonates | Q68170535 | ||
| Pharmacokinetic study of piperacillin in newborns relating to gestational and postnatal age | Q68207562 | ||
| [Gentamycin in pediatrics] | Q68217673 | ||
| Effect of cephalosporins on bilirubin-albumin binding | Q68259522 | ||
| Pharmacokinetics of intravenous metronidazole in neonates | Q68313647 | ||
| Treatment of Neonatal Sepsis with Cef triaxone/Gentamicin and with Azlocillin/Gentamicin: A Clinical Comparison of Efficacy and Tolerability | Q68433874 | ||
| Mild ischemia predisposes the S3 segment to gentamicin toxicity | Q68591103 | ||
| Assessment of tubular function in neonates using urinary beta 2-microglobulin | Q68606096 | ||
| Urinary beta-2-microglobulin excretion in prematures with respiratory distress syndrome | Q68675067 | ||
| Pharmacokinetics of aztreonam in very low birthweight neonates | Q68681333 | ||
| Pharmacokinetic and clinical evaluation of imipenem/cilastatin in children and neonates | Q68788911 | ||
| Lack of nephrotoxicity in pediatric patients receiving concurrent vancomycin and aminoglycoside therapy | Q69125970 | ||
| Clinical Pharmacology of Tobramycin in Newborns | Q69255122 | ||
| Penicillin treatment for congenital syphilis. A critical reappraisal | Q69339733 | ||
| Pharmacologic studies in neonates given large dosages of ampicillin | Q69351716 | ||
| The pharmacokinetics of ticarcillin/clavulanate acid in neonates | Q69417709 | ||
| Ceftriaxone effect on bilirubin-albumin binding | Q69454887 | ||
| What is the cost of nephrotoxicity associated with aminoglycosides? | Q69462800 | ||
| A model for predicting nephrotoxicity in patients treated with aminoglycosides | Q69493303 | ||
| Clinical pharmacology of penicillin in newborn infants | Q69503854 | ||
| Levels of penicillin in serum of newborn infants after single intramuscular doses of benzathine penicillin G | Q69515851 | ||
| Successful response of severe neonatal gram-negative infection to treatment with aztreonam | Q69627381 | ||
| Serum levels of ampicillin and gentamycin in neonates of varying gestational age | Q69640283 | ||
| [Determination of aminoglycosides in the newborn infant. Significance and methods] | Q69648833 | ||
| Serum netilmicin levels in premature AGA infants | Q69684407 | ||
| [Cephalosporins and enzymuria] | Q69878135 | ||
| Enzymuria in neonates during treatment with tobramycin or ceftazidime | Q69913762 | ||
| Gentamicin in the Neonatal Period | Q69921691 | ||
| Vancomycin pharmacokinetics in small, seriously ill infants | Q70009545 | ||
| Postconceptional age and gentamicin elimination half-life | Q70062226 | ||
| Possible indomethacin-aminoglycoside interaction in preterm infants | Q70062229 | ||
| Clinical pharmacology of netilmicin in preterm and term newborn infants | Q70075237 | ||
| Single-dose ceftriaxone kinetics in the newborn | Q70085974 | ||
| Vancomycin/aminoglycoside nephrotoxicity | Q70113964 | ||
| Prospective evaluation of a vancomycin dosage guideline for neonates | Q70127906 | ||
| Metabolic tolerance to arginine: implications for the safe use of arginine salt-aztreonam combination in the neonatal period | Q70169954 | ||
| Clindamycin | Q70220864 | ||
| Association of intravenous lipid emulsion and coagulase-negative staphylococcal bacteremia in neonatal intensive care units | Q70258795 | ||
| Pharmacokinetics and tissue distribution of metronidazole in the new born infant | Q70290957 | ||
| Continuous intravenous infusion of ampicillin and gentamicin during parenteral nutrition to 36 newborn infants using a dosage schedule | Q70487562 | ||
| Initiation of chloramphenicol therapy in the newborn infant | Q70517796 | ||
| Individualized pharmacokinetic profiles to compute vancomycin dosage and dosing interval in preterm infants | Q70545152 | ||
| Effect of ampicillin versus cefuroxime on the emergence of beta-lactam resistance in faecal Enterobacter cloacae isolates from neonates | Q70588905 | ||
| Adverse effects of methicillin, nafcillin and oxacillin in pediatric patients | Q70598426 | ||
| Staphylococcus epidermidis bacteremia in neonates: further observations and the occurrence of focal infection | Q70656693 | ||
| The need for pharmacokinetic monitoring of gentamicin therapy in critically ill neonates | Q70733391 | ||
| Cerebrospinal fluid concentrations of aqueous procaine penicillin G in the neonate | Q70806602 | ||
| Metronidazole | Q70983256 | ||
| Chloramphenicol pharmacokinetics in the newborn | Q71065638 | ||
| Pharmacology and efficacy of vancomycin for staphylococcal infections in children | Q71108855 | ||
| The pharmacokinetics of chloramphenicol in the neonate and young infant | Q71169116 | ||
| Relatively penicillin-resistant pneumococcal infections in pediatric patients | Q71369609 | ||
| The management of pneumonia in children in developing countries | Q71373637 | ||
| Use of chloramphenicol palmitate in neonates | Q71397040 | ||
| Drugs and the neonatal kidney | Q71444564 | ||
| P433 | issue | 3 | |
| P921 | main subject | antibiotic | Q12187 |
| P304 | page(s) | 405-427 | |
| P577 | publication date | 1999-09-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Antibiotics in neonatal infections: a review | |
| P478 | volume | 58 |
| Q37358644 | A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants |
| Q34224058 | Aetiology and management of children with acute fever of unknown origin |
| Q24186010 | Antimicrobial dressings for the prevention of catheter-related infections in newborn infants with central venous catheters |
| Q37808477 | Are rats the appropriate experimental model to understand age-related renal drug metabolism and toxicity? |
| Q33957919 | C-reactive protein and serum amyloid A protein in neonatal infections. |
| Q37948766 | Cefotaxime-induced near-fatal anaphylaxis in a neonate: A case report and review of literature |
| Q35292492 | Dose regimen for vancomycin not needing serum peak levels? |
| Q40531697 | Effects of antibiotic stewardship on neonatal bloodstream infections |
| Q38880999 | Empirical gentamicin dosing based on serum creatinine levels in premature and term neonates |
| Q38437368 | Evaluating and managing neonatal acute renal failure in a resource-poor setting |
| Q35790201 | Evaluating the near-term infant for early onset sepsis: progress and challenges to consider with 16S rDNA polymerase chain reaction testing |
| Q47833944 | Evaluation of a System-specific Function to Describe the Pharmacokinetics of Benzylpenicillin in Term Neonates Undergoing Moderate Hypothermia. |
| Q44591792 | Experimental study of teicoplanin, alone and in combination, in the therapy of cephalosporin-resistant pneumococcal meningitis. |
| Q34014285 | Inadequate vancomycin therapy in term and preterm neonates: a retrospective analysis of trough serum concentrations in relation to minimal inhibitory concentrations |
| Q56922129 | Infections of the nervous system |
| Q44603327 | Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens |
| Q38045406 | Metabolic and toxicological considerations for sepsis drug treatments. |
| Q36381238 | N-acetylcysteine as a potential antidote and biomonitoring agent of methylmercury exposure. |
| Q36116444 | Neonatal chlamydial infections: prevention and treatment |
| Q34558661 | Nosocomial pneumonia in pediatric patients: practical problems and rational solutions |
| Q73304053 | Pharmacokinetics and dosing of arbekacin in preterm and term newborn infants |
| Q33826426 | Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. |
| Q87630666 | Pharmacological aspects of anti-infective therapy in neonates |
| Q43426955 | RT-PCR detection of respiratory pathogens in newborn children admitted to a neonatal medium care unit |
| Q35790010 | Real-time polymerase chain reaction for detecting bacterial DNA directly from blood of neonates being evaluated for sepsis |
| Q37271754 | Scientific rationale for study design of community-based simplified antibiotic therapy trials in newborns and young infants with clinically diagnosed severe infections or fast breathing in South Asia and sub-Saharan Africa |
| Q37273015 | Simplified regimens for management of neonates and young infants with severe infection when hospital admission is not possible: study protocol for a randomized, open-label equivalence trial |
| Q43640000 | Six day antimicrobial therapy for early-onset group B streptococcal infection in near-term and term neonates |
| Q53915294 | Study of correlations between antibiotics prescriptions and guidelines in a neonatal intensive care unit |
| Q34170056 | Systematic review: neonatal meningitis in the developing world |
| Q36410220 | Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics |
Search more.